Entecavir pharma-grade API is supplied as the crystalline monohydrate, CAS 142217-69-4, molecular formula C₁₂H₁₅N₅O₃·H₂O, and molecular weight 295.29 g/mol. The product is designated for formulation into immediate-release tablets, capsules, granules for oral suspension, oral solutions, and sterile injectable presentations. Release and stability testing are aligned with current ICH Q1A, Q3C, Q3D, Q6A, and Q7 guidance; analytical procedures reference USP <621>, USP <921>, USP <467>, USP <232>, and USP <233> as applicable. The API is manufactured under a quality system derived from ICH Q7, with change control for synthetic intermediates and crystallisation solvents.

What compendial and ICH specifications govern release of entecavir monohydrate?

The certificate of analysis for each lot typically reports appearance, identification, water content, assay, related substances, residual solvents, elemental impurities, residue on ignition, and microbial limits. Identity is confirmed by infrared absorption against a qualified reference standard and by reversed-phase HPLC retention time. Water content is determined by Karl Fischer titration and is controlled between 5.5% and 6.5%, consistent with the theoretical water content of the monohydrate. HPLC assay on the anhydrous, solvent-free basis is controlled at 98.0%–102.0%. Impurity thresholds are set according to ICH Q3A for daily doses below 1 g; unspecified impurities are limited to not more than 0.10%, and total impurities to not more than 0.5%. Residual solvent limits follow ICH Q3C for the synthesis solvents actually used; Class 3 solvents are limited to 5000 ppm unless otherwise justified, and Class 2 solvents are controlled below their permissible daily exposure equivalents.

Particle-size distribution for solid oral dosage is selected according to the intended unit operation. For low-dose direct compression blends, micronized entecavir monohydrate with a laser-diffraction D90 of 20 µm to 60 µm is used to increase specific surface area and reduce segregation. The measurement is performed as a dry dispersion per ISO 13320:2020 at a dispersing air pressure of 0.5 bar to 4.0 bar. A coarser grade with D90 80 µm–150 µm may be selected for wet granulation or roller compaction to limit dusting and static charge. Bulk and tapped density are monitored using USP <616>, with lot-to-lot control to the approved reference range rather than universal limits.

Because the API is active at sub-milligram doses, cross-contamination control during batch changeover is a dominant manufacturing risk. Dedicated or multi-product facilities use contained transfer systems, single-use charge bags, and validated cleaning with analytical detection limits derived from the next-product acceptable daily exposure or permitted daily exposure. Visual clean inspection alone is insufficient for this potency class; swab and rinse sampling must be supported by HPLC or LC-MS methods capable of reaching the calculated residue limit. Cleaning validation reports therefore include the specific product changeover sequence and the health-based limit calculation.

When roller compaction replaces direct compression at low dose

When the formulation route shifts from direct compression to roller compaction because of flow limitations at 0.5 mg or 1.0 mg tablet strengths, the API particle-size specification is usually relaxed to the coarser grade; however, the risk of ribbon lamination and loss of compaction during milling becomes dominant. The granulation process is designed with roller pressure between 4 kN/cm and 12 kN/cm and gap settings adjusted to produce ribbon densities between 0.8 g/cm³ and 1.1 g/cm³. Milling is performed through an oscillating granulator fitted with 0.8 mm or 1.0 mm screens; screen selection directly controls the proportion of fines below 75 µm. Excessive fines generated during dry granulation can reintroduce segregation and content uniformity failure in the final blend. The compression step is monitored on a rotary tablet press with 8 mm B-tooling and compression force adjusted to achieve tablet hardness of 35 N–70 N for a 100 mg core, depending on the disintegration specification. These ranges are formulation-dependent and must be re-qualified for each commercial batch record.

Capsule filling and dry granule manufacture create a different failure mode. For low-dose encapsulated products, the API is often blended with directly compressible lactose and croscarmellose sodium before filling into size 3 or size 4 hard gelatin capsules; the fill weight of 80 mg to 120 mg can produce acceptable content uniformity if the API is pre-dispersed by geometric dilution and the excipients are pre-sieved through 425 µm mesh. During automated capsule filling on an intermittent-motion dosator machine, static charge on the API can cause loss to metal surfaces and variability in fill weight. Humidity above 60% RH increases interparticle cohesion; pre-conditioning the blend at 25%–35% RH and adding 0.10%–0.25% colloidal silicon dioxide reduces triboelectric charging. The resulting granule or capsule blend is tested for uniformity of dosage units by USP <905>; an acceptance value not exceeding 15 is required before release for compression or encapsulation.

For oral solution preparation from granules or API powder, dissolution testing is not the release control; rather, the API is dissolved in purified water at a concentration of 0.05 mg/mL to 0.1 mg/mL and packaged with a preservative. The solution must be protected from light and stored in amber glass because photodegradation can reduce assay below specification over the intended storage period. The oral liquid formulation is filtered through a 0.45 µm clarifying filter to reduce visible particulates and then filled to volume; filter compatibility is tested for adsorption losses. Microbial quality for oral solution requires absence of Escherichia coli per USP <62>; total aerobic microbial count is limited to 10³ CFU/mL for nonsterile oral products.

Injectable-grade API requirements are not a subset of oral-grade controls

Entecavir monohydrate intended for sterile injectable presentations undergoes additional purification and environmental control because oral-grade material may contain higher bioburden, endotoxin, and particulate levels. Sterile API is processed in an ISO 7 cleanroom or through closed processing with terminal filtration; if the API itself is not terminally sterilized, the dissolved drug product is filtered through a sterilizing-grade membrane with a nominal pore size of 0.22 µm before aseptic filling. Endotoxin is measured by the limulus amebocyte lysate assay described in USP <85>; the limit is calculated from the maximum intended dose and the parenteral route. For a 0.5 mg daily dose, a parenteral specification may be established at not more than 0.25 EU/mg if the dose is administered as a single bolus, but the actual limit must be derived from the clinical protocol and regional regulator. Sterility testing is executed by membrane filtration per USP <71> with 14-day incubation; the API must also meet particulate matter limits after reconstitution per USP <788> when the final presentation is intended as an injectable solution. Buffering and tonicity adjustment are performed by the finished-dose manufacturer; the API itself is not self-preserving and must not be held as an unpreserved solution beyond the validated hold time.

The shift from oral-route grade to injectable-grade material is not merely a matter of final filtration. The API must be manufactured with reduced viable bioburden before filtration, because excessive pre-filtration bioburden can increase endotoxin load and block sterilizing-grade membranes. Pre-filtration bioburden is controlled to a site-specific alert level, commonly not more than 10 CFU/100 mL before the final 0.22 µm filter. The dissolved product is filtered at a pressure not exceeding the manufacturer-rated differential pressure for the selected membrane, typically below 2.5 bar for polyethersulfone capsules. Filter selection, prefiltration hold time, and temperature excursions are recorded as critical process parameters rather than as general operating notes.

When sterile filtration is the selected terminal sterilization process, the compatibility of entecavir monohydrate with the filter membrane and the solution pH becomes a critical process parameter. The weakly basic guanine analogue may bind to certain membrane matrices under low ionic strength conditions; filter-validation studies using a product-specific solution spiked at 1 µg/mL are conducted to exclude adsorption losses above 2%. The solution is typically prepared at pH between 6.0 and 7.5 to maintain adequate solubility; below pH 2.0 and above pH 10.0, prolonged hydrolytic exposure may accelerate degradation. Published data for this specific configuration is limited; therefore, each manufacturing site must generate filter-binding and hold-time data rather than relying on oral-grade stability profiles.

Stability, packaging, and distribution controls under ICH climatic zones

Stability studies for the API are conducted in accordance with ICH Q1A under long-term, intermediate, and accelerated conditions. The monohydrate is packaged in double low-density polyethylene bags inside an aluminum foil laminate pouch with desiccant, then placed in a high-density polyethylene drum. Storage is specified at 20 °C–25 °C with excursions permitted in 15 °C–30 °C per USP <659>. The material should be protected from light and high humidity. At relative humidity above 60% RH, the crystalline monohydrate can absorb surface moisture and exhibit caking without necessarily changing its formal hydrate form; drying at 40 °C or above must be validated because loss of lattice water near 100 °C may convert the material to the anhydrous phase. The release specification includes X-ray powder diffraction by USP <941> and differential scanning calorimetry to confirm the crystalline phase; dual endothermic events associated with dehydration and melting are monitored, but published reference thermograms vary with heating rate. Use after retest date is not recommended unless the lot is retested and meets all specifications.

Differences between this API and other hepatitis B antivirals arise from both molecular structure and dose magnitude. Entecavir is a deoxyguanosine nucleoside analogue with a carbocyclic sugar-like 2-methylenecyclopentyl group; it inhibits HBV polymerase priming, reverse transcription of the minus strand, and synthesis of the plus strand. Unlike tenofovir disoproxil fumarate and tenofovir alafenamide, entecavir does not contain a phosphonate moiety; this structural difference removes the phosphate-associated renal tubular handling pathway relevant to tenofovir-based products. Tablets for entecavir are manufactured at 0.5 mg or 1.0 mg label strength, whereas tenofovir disoproxil fumarate products are commonly 300 mg per tablet. The low dose requires stricter control of blend uniformity, surface adhesion, and analytical sensitivity during cleaning validation; health-based cleaning limits are calculated using acceptable daily exposure or permitted daily exposure values according to regional guidance. In addition, the pharma-grade monohydrate differs from anhydrous entecavir in water content, XRPD pattern, and compaction behavior. The anhydrous form, if generated by overdrying, may have a higher initial dissolution rate but presents uncontrolled water uptake; therefore the monohydrate is designated for solid oral dosage to avoid batch-to-batch variability during wet granulation.